Sun Pharma and Israel-based Moebius Medical announce USFDA grant of Fast Track ...
Sun Pharmaceutical Industries and Moebius Medical received FDA Fast Track designation for MM-II (Large Liposomes of DPPC and DMPC) to treat osteoarthritis knee pain, with Phase 3 clinical trials planned.
Related Clinical Trials
Reference News
US FDA fast tracks MM-II, a non-opioid knee OA pain injection co-developed by Sun Pharmaceutical and Moebius Medical, under a 2016 global licensing deal.
Sun Pharma and Moebius Medical receive FDA Fast Track designation for MM-II, a non-opioid treatment for osteoarthritis knee pain using large, empty, multilamellar liposomes. Phase 3 trials and CE Mark pursuit in the EU are planned.
Sun Pharmaceutical Industries and Moebius Medical received FDA Fast Track designation for MM-II (Large Liposomes of DPPC and DMPC) to treat osteoarthritis knee pain, with Phase 3 clinical trials planned.
Sun Pharma and Moebius Medical announced FDA Fast Track designation for MM-II in treating osteoarthritis knee pain, with Phase 3 clinical trials planned. The designation aims to expedite development and review of therapies addressing unmet medical needs.
Sun Pharma and Moebius Medical announce USFDA fast track designation for non-opioid therapy MM-II against osteoarthritis knee pain, with plans for Phase 3 trials and CE Mark in EU.
Sun Pharma and Moebius Medical's MM-II (large liposomes of DPPC and DMPC) received Fast Track designation from the FDA for treating osteoarthritis knee pain, with phase 3 trials planned. MM-II, a non-opioid, aims to reduce joint friction and wear, offering pain relief for up to 26 weeks. The companies also plan to seek a CE Mark for the product in the EU.
Sun Pharma and Moebius Medical receive Fast Track designation for MM-II, a treatment for osteoarthritis knee pain, from the FDA. Phase 3 clinical trials are planned.
Sun Pharma and Moebius Medical announced FDA Fast Track designation for MM-II, a treatment for osteoarthritis knee pain, with plans for Phase 3 trials underway.
Sun Pharma and Moebius Medical's MM-II (Large Liposomes of DPPC and DMPC) received FDA Fast Track designation for osteoarthritis knee pain treatment. MM-II, a non-opioid, uses large, empty, multilamellar liposomes to reduce joint friction and pain. Phase 2b study results showed significant pain relief for up to 26 weeks. Plans include Phase 3 clinical trials and seeking a CE Mark for the EU.
Sun Pharma and Moebius Medical announced USFDA fast track designation for non-opioid therapy MM-II against osteoarthritis knee pain, with plans for Phase 3 trials and CE Mark in the EU.
USFDA grants Fast Track Designation to Sun Pharmaceutical Industries and Moebius Medical's MM-II for osteoarthritis knee pain treatment. MM-II, a non-opioid product using large, empty, multilamellar liposomes, aims to reduce joint friction and pain. Plans include Phase 3 clinical trials and seeking a CE Mark for the EU.
Sun Pharmaceutical Industries and Moebius Medical received FDA fast track designation for MM-II, a non-opioid treatment for osteoarthritis knee pain. MM-II, based on large liposomes of DPPC and DMPC, demonstrated substantial pain relief in a Phase IIb trial. The designation aims to expedite development and review of treatments for serious conditions with unmet needs, potentially improving patient outcomes.
Sun Pharma and Moebius Medical's MM-II (Large Liposomes of DPPC and DMPC) received FDA Fast Track designation for osteoarthritis knee pain treatment, with Phase 3 trials planned. The designation aims to expedite development and review of therapies addressing unmet medical needs.
Sun Pharma and Moebius Medical receive FDA Fast Track Designation for MM-II, a non-opioid treatment for osteoarthritis knee pain, following positive Phase 2b data. Planning for Phase 3 trials and CE Mark application in EU is underway.